Tanvex BioPharma (TPE:6541) FCF Margin %: -353.76% (As of Dec. 2025)


TPE:6541 Tanvex BioPharma Inc TPE:6541
57 GF Score
Price NT$41.40
GF Value NT$254.61
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Tanvex BioPharma FCF Margin %?

Tanvex BioPharma TPE:6541 +2.10% 57 FCF Margin % is -353.76% as of Dec. 2025. GuruFocus rates TPE:6541 with a GF Score™ of 57/100 and a GF Value™ of NT$254.61 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 951 Biotechnology companies, Tanvex BioPharma ranks worse than 69.82% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Tanvex BioPharma's Free Cash Flow for the three months ended in Dec. 2025 was NT$-633.1 Mil. Tanvex BioPharma's Revenue for the three months ended in Dec. 2025 was NT$179.0 Mil. Therefore, Tanvex BioPharma's FCF Margin % for the quarter that ended in Dec. 2025 was -353.76%.

As of today, Tanvex BioPharma's current FCF Yield % is -15.27%.

The historical rank and industry rank for Tanvex BioPharma's FCF Margin % or its related term are showing as below:

TPE:6541' s FCF Margin % Range Over the Past 10 Years
Min: -618373.33   Med: -5009.92   Max: -417.9
Current: -417.9

During the past 13 years, the highest FCF Margin % of Tanvex BioPharma was -417.90%. The lowest was -618373.33%. And the median was -5009.92%.

TPE:6541's FCF Margin % is ranked worse than
69.82% of 951 companies
in the Biotechnology industry
Industry Median: -82.65 vs TPE:6541: -417.90

Tanvex BioPharma FCF Margin % Related Terms

Tanvex BioPharma FCF Margin % Historical Data

* Premium members only.

The historical data trend for Tanvex BioPharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tanvex BioPharma FCF Margin % Chart

Tanvex BioPharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -26,218.41 -6,382.46 -2,453.46 -3,637.37 -417.90

Tanvex BioPharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11,269.32 -596.10 -849.83 -277.23 -353.76

TPE:6541 vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, Tanvex BioPharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tanvex BioPharma FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tanvex BioPharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Tanvex BioPharma's FCF Margin % falls into.


TPE:6541
57GF Score
Tanvex BioPharma Inc TPE:6541
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tanvex BioPharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Tanvex BioPharma's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-1675.641/400.971
=-417.90 %

Tanvex BioPharma's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-633.056/178.953
=-353.76 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -353.76% mean?
Tanvex BioPharma (TPE:6541) has a FCF Margin % of -353.76% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Tanvex BioPharma and its competitors. According to the industry distribution chart, Tanvex BioPharma ranks #664 out of 951 companies in the Biotechnology industry, placing it in the top 69.8%.
Is Tanvex BioPharma's FCF Margin % too high?
Tanvex BioPharma's current FCF Margin % is -353.76%. Based on the distribution chart, Tanvex BioPharma ranks #664 out of 951 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Tanvex BioPharma has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tanvex BioPharma's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Tanvex BioPharma ranks #664 out of 951 companies for FCF Margin %. This places Tanvex BioPharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Tanvex BioPharma and its competitors. Tanvex BioPharma's current FCF Margin % is -353.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tanvex BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Tanvex BioPharma (TPE:6541) is currently considered Possible Value Trap. The stock's GF Value™ is NT$254.61, compared to a current price of NT$41.40 — trading 83.7% below its estimated fair value. The current FCF Margin % is -353.76%. Tanvex BioPharma's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Tanvex BioPharma (TPE:6541), the current FCF Margin % is -353.76% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tanvex BioPharma (TPE:6541) Overvalued in 2026?

Based on GuruFocus' analysis, Tanvex BioPharma stock appears to be undervalued. The current stock price of NT$41.40 is trading 83.7% below its estimated GF Value™ of NT$254.61. GuruFocus considers Tanvex BioPharma to be Possible Value Trap.

Key valuation signals for TPE:6541:

  • FCF Margin %: -353.76%
  • GF Value™: NT$254.61 vs. price of NT$41.40 (83.7% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the TPE:6541 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tanvex BioPharma Business Description

Address No. 12-2, Shengyi Road, Section 2, 6th Floor, Hsinchu County, Zhubei, TWN, 106
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company operates in Asia, America, Europe, and Australia. The company generates a majority of its revenue from the USA.
57GF Score

Get the complete analysis for TPE:6541

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$41.40
Price
NT$254.61
GF Value